D. Gaál

发表

Attenuation of the development of murine solid leukemia tumor by physical exercise.

T. Kaneko, S. Goto, Z. Radák, 2002, Antioxidants & redox signaling.

New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.

J. Molnár, H. Lage, A. Hevér, 2004, Anticancer research.

Drug targeting by macromolecules without recognition unit?

G. Kóczán, J. Reményi, P. Kovács, 2003, Journal of molecular recognition : JMR.

Carrier design: cytotoxicity and immunogenicity of synthetic branched polypeptides with poly(L-lysine) backbone

E. Rajnavölgyi, F. Hudecz, A. Kovács, 1992 .

Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant L1210 strain associates with collateral sensitivity to cyclophosphamide

L. Tretter, D. Gaál, E. Institóris, 2004, Cancer Chemotherapy and Pharmacology.

The effect of regular exercise on development of sarcoma tumor and oxidative damage in mice liver.

Z. Radák, M. Sasvári, A. W. Taylor, 2011, Journal of sports science & medicine.

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

R. Murphy, S. Lovas, J. Pató, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Telomerase activity is not altered by regular strenuous exercise in skeletal muscle or by sarcoma in liver of rats

A. Taylor, T. Kanel, H. Ohno, 2001, Redox report : communications in free radical research.

Gamma scintigraphy of111In-labelled branched chain polypeptides (BCP) with a poly(L-lysine) backbone in mice with mammary carcinoma: Effect of charge on biodistribution and tumour imaging potential

A. Perkins, F. Hudecz, M. Pimm, 1995, Annals of nuclear medicine.

Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.

G. Kéri, O. Csuka, M. Tejeda, 2005, Anticancer research.

Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide.

F. Hudecz, D. Gaál, 1998, European journal of cancer.

The Theology of Pope Benedict XVI

Emery, D. Gaál, 2010 .

Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug.

M. Przybylski, S. Bősze, A. Csámpai, 2009, Bioconjugate chemistry.

A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo

G. Kulcsár, Ákos Schulcz, T. Czömpöly, 2012, International journal of cancer.

The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen.

A. Ullrich, G. Kéri, O. Csuka, 2003, Cancer detection and prevention.

Carrier design: new generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity.

E. Rajnavölgyi, F. Hudecz, G. Mező, 1999, Bioconjugate chemistry.

Synthetic branched polypeptides as carriers for low-molecular-weight antigens: correlation between chemical structure and biological functions

J. Gergely, F. Hudecz, G. Mező, 1990 .

Branched Polypeptides with a Poly(L-Lysine) Backbone: Synthesis, Conformation, and Immunomodulation

H. Votavova, J. Šponar, F. Hudecz, 1985 .

In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.

J. Pató, J. Seprődi, I. Teplán, 1996, Cancer Detection and Prevention.

A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.

A. Ullrich, G. Kéri, O. Csuka, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models.

G. Kéri, O. Szokolóczi, R. Schwáb, 2007, Anticancer research.

Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.

G. Kéri, B. Hegymegi-Barakonyi, M. Tejeda, 2006, Anticancer research.

The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.

G. Kéri, O. Csuka, M. Tejeda, 2003, Anticancer research.

In vivo antitumor activity of TT-232 a novel somatostatin analog.

G. Kéri, Á. Pap, R. Schwáb, 1999, Anticancer research.

A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.

G. Kéri, O. Csuka, O. Szokolóczi, 2006, Anticancer research.

Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.

G. Kéri, O. Csuka, O. Szokolóczi, 2008, Anticancer research.

Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog.

G. Kéri, T. Szűts, Á. Pap, 2000, Anticancer research.

Synthesis, conformation, and immunoreactivity of new carrier molecules based on repeated tuftsin‐like sequence

J. Reményi, L. Köhidai, O. Láng, 2004, Biopolymers.

Synthesis and conformational studies of poly(L-lysine) based branched polypeptides with Ser and Glu/Leu in the side chains.

J. Reményi, F. Hudecz, G. Mezö, 2000, Journal of controlled release : official journal of the Controlled Release Society.

Thermodynamic Aspects of Cancer: Possible Role of Negative Entropy in Tumor Growth, its Relation to Kinetic and Genetic Resistance

Liaofu Luo, Annamária Molnár, Elke S. Bergmann-Leitner, 2005 .

The effect of regular exercise on development of sarcoma tumor and oxidative damage in mice liver.

Z. Radák, M. Sasvári, A. W. Taylor, 2011, Journal of sports science & medicine.